about
Diabetes and hypertension increase the placental and transcellular permeation of the lipophilic drug diazepam in pregnant women.Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes.Warfarin interactions with medicinal herbs.Reasons for and frequency of off-label drug use.The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes.[Orphan drugs].Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics.Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat.Comparison of dissolution profiles and serum concentrations of two lamotrigine tablet formulations.Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study.Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats.Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol.Cefotaxime pharmacokinetics after oral application in the form of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate microvesicles in rat.Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats.The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes.Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats.Interaction between different extracts of Hypericum perforatum L. from Serbia and pentobarbital, diazepam and paracetamol.High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect.The Effect of Diabetes and Hypertension on the Placental Permeation of the Hydrophilic Drug, Ranitidine.Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects.Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes.Decreased placental and transcellular permeation of cefuroxime in pregnant women with diabetes.Docking-based preliminary study on the interactions of bile acids with drugs at the transporter level in intestinal bacteriaNovel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro studyRelease and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatmentAn advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulationsEffect of Simultaneous Exposure to Benzene and Ethanol on Urinary Thioether ExcretionProbiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic ratsThe influence of probiotics on the cervical malignancy diagnostics qualityCounterfeit drugs as a global threat to healthBioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3α,7α-dihydroxy-12-0X0-5β-cholanate, in healthy and diabetic rats
P50
Q35019769-F69BDB38-EB7B-4D2B-888C-96B682A15AC3Q35024360-3A575544-C7A5-4A11-9AE1-130103E03C31Q38252334-1881999E-4AD6-45D0-A015-F044A254127BQ38503166-9011072C-E580-47CF-A118-011574C1E075Q38769600-07FE3080-3767-4EE2-88DD-3AE0030079C6Q39217138-6296233E-6B32-4283-840B-F2C8BADAC24FQ39351329-BABFAE40-405B-4403-A8C8-6944751522DDQ40509847-C746AB7E-BAEF-44ED-AE2A-0E9DB64196DBQ41963089-9DCB95B5-B03D-4E69-83D8-862A70E8CFFCQ42770089-52268459-1075-423D-A323-A504F27ED61FQ42921986-7F11B08C-B003-40D1-A8AD-9CFDE6219CFAQ43808142-404148EB-DE79-4FBC-BFDB-4B6E841F6B02Q44236698-86E64C13-5647-4EA8-B71A-648A687AA398Q46000543-63D9EC9E-7857-4C4C-A255-51B3493A5C58Q46248679-DF43B3BA-ED14-443A-996E-D3404505F9D8Q46382050-39EB86EE-EA3C-4331-B4D6-FD4F88D31BFCQ47890544-9393744E-5D33-4484-8DA9-4A7EFD21AEC0Q48089000-491F2561-6012-418B-B9E9-FC91C2E46C22Q51053843-554C9AAC-235D-46D7-8FBC-3160C1CAE8AEQ52867250-3B64BBB0-BBFE-48C8-92AA-B671FCC9ABC3Q53281341-19C167CD-713A-46A3-B881-F7DD3792281FQ53568751-28DA2E96-04E0-4575-810A-1D03AC6F5767Q57139830-A387C85B-EDCF-4961-87D9-DE4C59693187Q57147903-7EA9748C-058E-44F3-91C3-BA1FC8222400Q57147909-29E56764-1F94-45BE-8748-7493EEB7B560Q57148084-92A7F3AA-C7CC-4888-AF02-3327E1F8893CQ59258131-2AFE5660-680F-4A36-B7C5-99911922EB94Q60393898-746C932C-8A2C-47DC-9C8E-F7C20F18A6B8Q60393899-EB489AE4-5491-40BF-B0BE-4ED3B51BB017Q60393901-B9D343F3-A8B0-49A7-AA22-EBD510B0820DQ60393909-8B45D614-3249-4B9B-95C8-AB3639A806BB
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Svetlana Golocorbin-Kon
@ast
Svetlana Golocorbin-Kon
@en
Svetlana Golocorbin-Kon
@es
Svetlana Golocorbin-Kon
@nl
Svetlana Golocorbin-Kon
@sl
type
label
Svetlana Golocorbin-Kon
@ast
Svetlana Golocorbin-Kon
@en
Svetlana Golocorbin-Kon
@es
Svetlana Golocorbin-Kon
@nl
Svetlana Golocorbin-Kon
@sl
prefLabel
Svetlana Golocorbin-Kon
@ast
Svetlana Golocorbin-Kon
@en
Svetlana Golocorbin-Kon
@es
Svetlana Golocorbin-Kon
@nl
Svetlana Golocorbin-Kon
@sl
P106
P21
P2798
P31
P496
0000-0002-9257-8074